Potential Mega-Deal for Pfenex (PFNX); Upside Visualized In Ballard Power Systems (BLDP)

Pfenex_PFNX

Shares of Pfenex Inc. (NYSEMKT:PFNX) climbed more than 5% in the extended session Thursday after the company said that it has entered into a license agreement with Irish drugmaker Jazz Pharmaceuticals plc (Nasdaq:JAZZ) to develop and commercialize multiple early stage drugs for hematological malignancies

As part of the deal, Pfenex will receive from Jazz Pharma a $15 million upfront payment with potential – may be eligible – for up to additional $166 million based on the achievement of pre-determined product milestones

PFNX stock finished the regular session in negative territory by 2.78% (or -$0.23) at $8.03 and 48,099 of its shares changed hands during the day

Pfenex, which is engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins, has 23.38M Shares Outstanding and PFNX stock 52-week range is from $5.78 to $22.75 per share. At close on Thursday, the company had a Market Capitalization of $205.36M

*

Ballard_Power_Systems_BLDP

Investment analysts at FBR Capital upgraded Ballard Power Systems Inc. (Nasdaq:BLDP) shares from a Market Perform to an Outperform rating and raised their price target from $1.50 to $3.00

BLDP stock touched a new 52-week high of $2.15 in intraday trading Thursday, finally closing at $2.01, down $0.03 (or -1.47%) with a total volume of 3,095,589 shares traded, representing a large increase in activity versus its average volume (3m) of 1,179,191

Ballard Power Systems, which engages in the development and commercialization of proton exchange membrane fuel cells worldwide, has 156.89M Shares Outstanding, Market Capitalization (intraday) of $348.93M and BLDP stock one-year range is now between $1.07 and $2.15 per share

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/